An Eastern Cooperative Oncology Group Phase II Study of Single Agent DHAD, VP-16, Aclacinomycin, or Spirogermanium in Metastatic Pancreatic Cancer
- 1 April 1994
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 17 (2) , 166-169
- https://doi.org/10.1097/00000421-199404000-00016
Abstract
There were 80 patients with measurable metastatic or unresectable pancreatic cancer randomly assigned to treatment with either DHAD, VP-16, aclacinomycin, or spirogermanium. There were no complete or partial responses. Two deaths from leukopenia occurred in patients treated with DHAD. One patient receiving spirogermanium experienced a seizure. No other life-threatening toxicities occurred. Maximal toxicities were not significantly more frequent with any treatment group. Median survival was 10 weeks, and median time to progression was only 6 weeks, with no difference among these four therapies.Keywords
This publication has 0 references indexed in Scilit: